Kevin Weil’s Warp Sciences Raises $215 Million for AI Drug Research
Photo: TokenPost
Kevin Weil, formerly the AI-for-science leader at OpenAI, is launching Warp Sciences with $215 million to automate molecule testing in the United States and offer an alternative to work handled by Chinese firms. Lightspeed Venture Partners led the financing, with IVP, Premji Invest and Lux Capital also participating. The investment values Warp at $865 million after the financing. Angel backers include executives and founders from OpenAI, Coinbase, Palantir and LinkedIn. Researchers first identify promising drug candidates.
Source: TokenPost
